Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Alderuccio on the Use of Proteasome Inhibitors in Frontline Myeloma

April 17th 2019

Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.

Dr. Madduri on Challenges in Transplant-Eligible Patients With Myeloma

April 13th 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses challenges in the transplant-eligible myeloma population.

Dr. Hoffman Discusses Challenges in Relapsed/Refractory Myeloma

April 12th 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.

Dr. Raje on Treatment Approaches for Relapsed/Refractory Myeloma

April 8th 2019

Noopur Raje, MD, professor of medicine at Harvard Medical School and director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center, discusses treatment approaches for patients with relapsed/refractory multiple myeloma.

Carfilzomib Continues to Show Frontline Potential in Myeloma

April 8th 2019

Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain.

Dr. Lonial on Encouraging Data With Emerging Agents in Myeloma

April 5th 2019

Sagar Lonial, MD, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses encouraging data with emerging agents in myeloma.

Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT

April 2nd 2019

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.

Dr. Hoffman on Anticipated Developments in Multiple Myeloma

April 2nd 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses anticipated developments in the field of multiple myeloma.

EU Panel Backs Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

March 29th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted positive opinions to 2 triplet regimens with immunomodulatory agents for patients with multiple myeloma.

EU Application Filed for Daratumumab in Newly Diagnosed, Transplant-Eligible Myeloma

March 27th 2019

A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.

FDA Approval Sought for Frontline Daratumumab Regimen in Transplant-Eligible Myeloma

March 26th 2019

A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Emerging Treatments in Multiple Myeloma Spark Prospect for Cure

March 26th 2019

James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.

EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma

March 23rd 2019

A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

BCMA Antibody-Drug Conjugate Continues to Extend PFS in Relapsed/Refractory Myeloma

March 22nd 2019

The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.

Dr. Cho on Promising Combinations in Multiple Myeloma

March 20th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses promising combinations in multiple myeloma.

Dr. Holstein on BiTEs in Multiple Myeloma

March 19th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

FDA Halts Enrollment on Venetoclax Myeloma Trials

March 19th 2019

The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies.

Dr. Berdeja Discusses Anticipated Research in Multiple Myeloma

March 19th 2019

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses anticipated research in the field of multiple myeloma.

Usmani Elucidates Management of Early Relapse in Multiple Myeloma

March 18th 2019

Saad Z. Usmani, MD, shares insight on approaches to early relapse in myeloma given the evolution of frontline treatment advances.

FDA Extends Review Period for Selinexor in Myeloma

March 15th 2019

The FDA has added 3 months to the review period for a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma, making the new action date July 6, 2019.